Bristol-Myers Agrees To Clean Air Act Upgrades

Law360, New York (July 8, 2008, 12:00 AM EDT) -- Bristol-Myers Squibb Co., the New York-based pharmaceutical manufacturer, has agreed to resolve alleged violations of the Clean Air Act by reducing the output of ozone-depleting refrigerants at five industrial facilities at a combined cost of $3.65 million.

In a consent decree filed Tuesday in the U.S. District Court for the Southern District of Indiana, Bristol-Myers agreed to take measures to remove over 6,350 pounds of harmful refrigerants from its facilities.

The drugmaker will also take additional steps to assure compliance with Environmental Protection Agency regulations at...
To view the full article, register now.